[Form 4] PFIZER INC Insider Trading Activity
Joseph J. Echevarria, a Director of Pfizer Inc. (PFE), reported an acquisition on 09/30/2025 of 1,815.149 phantom stock units that represent deferred director compensation. The filing shows these units were recorded as acquired with a per-share reference price of $25.48 and that 1,815.149 underlying common shares correspond to the units.
The form states these phantom units are deferred compensation that will be settled in cash or common stock at the director's election following the reporting person’s retirement from the Board. After the reported transaction the filing lists 144,989.542 common shares as beneficially owned. The form was signed by an attorney on behalf of Mr. Echevarria on 10/02/2025.
- 1,815.149 phantom units were recorded as deferred compensation aligning director pay with shareholder value
- Phantom units include dividend equivalents, preserving economic alignment with stock performance until settlement
- Units may be settled in common stock, which could increase outstanding shares if elected
- Filing shows a contingent obligation tied to director compensation that could require cash or share settlement
Insights
Director received deferred-compensation phantom units; settlement choices affect future share count.
The report documents acquisition of 1,815.149 phantom stock units on 09/30/2025 recorded as deferred director compensation. These units convert to either cash or common stock at the director's election after retirement, which means the company carries a contingent obligation tied to board pay.
This matters because the chosen settlement method—cash versus stock—will determine whether there is future cash outflow or potential share issuance, affecting Pfizer's cash and share count when settled.
Phantom units reflect standard deferred director pay with dividend equivalents; amount is modest relative to total holdings.
The filing clarifies each unit equals one phantom share and includes dividend equivalents; 1,815.149 units were granted as deferred pay. These are routine mechanisms to align director compensation with shareholder value without immediate stock transfer.
Because settlement can be in stock or cash, the practical impact depends on the director's future election and the company's settlement policy; the report shows 144,989.542 beneficial shares following the transaction, providing context for scale.